Safety and Efficacy of Low-dose IL-2 in Allergy to Birch Pollen
Status:
Unknown status
Trial end date:
2020-06-22
Target enrollment:
Participant gender:
Summary
Several studies have reported a deficit and/or a defect in regulatory T cells in allergic
subjects, which can be correlated with the immune dysfunction of allergic responses,
especially for respiratory allergies. Low-dose IL-2 (ld-IL2) acts to specifically target and
activate regulatory T cells, which are cells that exert targeted immunosuppressive action.
Thus by stimulating regulatory T cells, ld-IL2 would restore a balance of allergic responses
and protection by controls of allergic mechanisms.